Biogen Inc. said it is investigating the recent death of a 75-year-old patient who had taken the company’s new Alzheimer’s drug Aduhelm. After taking Aduhelm, the patient was hospitalized and ...

Biogen Inc. BIIB -1.48% said it is investigating the recent death of a 75-year-old patient who had taken the company’s new Alzheimer’s drug Aduhelm. After taking Aduhelm, the patient was ...

A Rhode Island man became the first patient worldwide to receive Biogen’s hotly debated Alzheimer’s drug outside of a clinical trial on Wednesday, a hospital spokesperson confirmed to Fox News.

Pharmaceutical company Biogen is investigating the death of a patient who had taken the company’s controversial Alzheimer’s drug Aduhelm, though it is not yet clear if there is any link. The ...

Biogen expects to launch IMRALDI in Europe on October 16, 2018, which will complement its existing portfolio of anti-TNF therapies, BENEPALI™ (etanercept) and FLIXABI™ (infliximab).